For almost a decade CHI's Immuno-Oncology Summit has been the leading annual conference providing the latest applied immuno-oncology research and supplying comprehensive and in-depth coverage across all modalities and stages in the pipeline. Each year, we assemble a melting pot of thought leaders from industry and academia to bring you the latest developments in immuno-oncology. The Summit provides access to a comprehensive three-day program and extensive networking opportunities.
Don't miss our 30-minute presentation taking place during the Preclinical and Translational Models track on Thursday, October 5th at 3 p.m.
Implantable Microdevices: Changing the Game for In Vivo Pharmacology Studies
Oliver Jonas, PhD, Scientific Founder, Kibur Medical; and Assistant Professor in Radiology, Harvard Medical School
The implantable microdevice (IMD) is a translational tool that allows us to systematically screen many individual and combination therapies in a small cohort of study animals.
This session outlines how IMDs function, and how we use them to facilitate the collection of robust data for numerous applications including:
- Combination screening
- Testing of compounds that have no PK or toxicology data
- Candidate comparison
- Specific biology, e.g., candidate interaction with TME
- Clinical translation
Charles River is pleased to also contribute to the scientific program with the below poster.
Where and What Off-target Assessments Using Tissue Cross-reactivity (TCR) and Retrogenix Cell Microarray Technologies | Nick Brown, Senior North American Business Development Manager, Retrogenix, a Charles River Company
Are you interested in meeting with one of our expert scientists? Complete the form to the right, and we’ll be in touch with scheduling options.